Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Healthcare Times Denmark.
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
GlobeNewswire, Inc.
·
March 31, 2025
Company announcement – No. 8 / 2025 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Building bridges between Denmark-based and Broad researchers
Broad Institute of MIT and Harvard
·
March 27, 2025
When Maddie Murphy, a computational associate at the Broad Institute of MIT and Harvard, first learned she’d have the opportunity to pursue her research in Copenhagen, she envisioned a two- or three-week visit. Then her supervisor, Ray Jones, told...
Clinical Trials Market Size to Hit Around USD 186.09 Billion by 2034
GlobeNewswire, Inc.
·
February 13, 2025
Ottawa, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The global clinical trials market size was valued at USD 120.98 billion in 2024 and is expected to hit around USD 186.09 billion by 2034 with a CAGR of 4.4% from 2025 to 2034, a study published by...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
GlobeNewswire, Inc.
·
March 28, 2025
THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin...
Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia
GlobeNewswire, Inc.
·
April 3, 2025
BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting...
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
GlobeNewswire, Inc.
·
March 25, 2025
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the structural integrity of the...
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
GlobeNewswire, Inc.
·
March 25, 2025
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the structural integrity of the...
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
GlobeNewswire, Inc.
·
March 25, 2025
Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on...
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
GlobeNewswire, Inc.
·
March 24, 2025
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
GlobeNewswire, Inc.
·
March 20, 2025
Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology...
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
GlobeNewswire, Inc.
·
March 17, 2025
Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate...
Frozen Dessert Market Set to Expand Significantly by 2032 Amid Growing Demand for Indulgent and Health-Conscious Treats
EIN Presswire
·
March 25, 2025
Frozen Dessert Market Research Report Information By Product, By Category, By Distribution Channel, And By Region– Market Forecast Till 2032 NEW YORK, NY, UNITED STATES, March 25, 2025 /EINPresswire.com/ -- According to Market Research Future...
Reengineering the global food system for a healthier planet
MIT Climate Portal - Massachusetts
·
March 22, 2025
By Mark Dwortzan | MIT Center for Sustainability Science and Strategy Study shows how ‘optimized’ diets could reduce malnutrition and environmental degradation “You are what you eat.” When it comes to the Earth and humanity, that phrase might well...
Healthcare Adhesive Tapes Market Estimation Worth USD 15.43 Billion By 2030 –Exactitude Consultancy
EIN Presswire
·
January 29, 2025
Global Healthcare Adhesive Tapes Market Include - Medtronic PLC, 3M Company, Avery Dennison Corporation, Medline Industries CALIFORNIA, CA, UNITED STATES, January 29, 2025 /EINPresswire.com/ -- A newly released report on the Healthcare Adhesive...
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
GlobeNewswire, Inc.
·
March 17, 2025
The Annual Meeting is the foremost educational and scientific event for gynecologic oncologists Stenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancer Findings...
Anocca Announces Authorisation of Clinical Trial Application to Start First In-Human Trial in Advanced Pancreatic Cancer
GlobeNewswire, Inc.
·
March 17, 2025
CTA approval marks Anocca’s transition to a clinical-stage company First-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced Pancreatic Cancer at leading medical centres in Sweden, Denmark, Germany and The Netherlands The...
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
GlobeNewswire, Inc.
·
March 19, 2025
CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of...
Azalee Group Hosts Copenhagen Honours College Nursing Students for Knowledge Exchange on Inclusive Care
EIN Presswire
·
March 17, 2025
TOKYO, JAPAN, March 17, 2025 /EINPresswire.com/ -- Azalee Group recently welcomed nursing students from the Copenhagen Honours College at the University College of Copenhagen for an international exchange on elderly care, intergenerational...
Upcycled Fashion Market Predicated To Reach USD 16.7 Billion 2032, to Grow at a CAGR of 8.1% From 2025 To 2032
EIN Presswire
·
July 2, 2025
Upcycled Fashion Market revenue is expected to grow at a CAGR of 8.1% from 2025 to 2032, reaching nearly USD 16.7 Bn. ATLANTA, GA, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- Stellar Market Research examines the growth rate of the Upcycled...
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
GlobeNewswire, Inc.
·
March 12, 2025
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity The companies will...